Stoke Therapeutics (STOK) Capital Expenditures (2018 - 2026)

Stoke Therapeutics' Capital Expenditures history runs 9 years deep, the most recent figure standing at $334000.0 for Q1 2026.

• In Q1 2026, Capital Expenditures rose 119.74% year-over-year to $334000.0; the TTM figure through Mar 2026 stood at $664000.0 (up 220.77% YoY), while the FY2025 annual figure was $482000.0, up 690.16% from the prior year.
• Capital Expenditures was $334000.0 for Q1 2026 at Stoke Therapeutics, up from $44000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $3.6 million in Q4 2022 to a low of -$1.1 million in Q3 2022.
• Historically, Capital Expenditures has averaged $379705.9 across 5 years, with a median of $229000.0 in 2023.
• Biggest YoY gain for Capital Expenditures was 2433.33% in 2025; the steepest drop was 1583.33% in 2025.
• A 5-year view of Capital Expenditures shows it stood at $3.6 million in 2022, then sank by 93.56% to $229000.0 in 2023, then sank by 143.67% to -$100000.0 in 2024, then jumped by 144.0% to $44000.0 in 2025, then surged by 659.09% to $334000.0 in 2026.
• The last three Capital Expenditures figures came in at $334000.0 (Q1 2026), $44000.0 (Q4 2025), and $387000.0 (Q3 2025), per Business Quant data.